Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.
Martínez-Jañez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Martínez-Jañez N, et al. Among authors: chacon i. Breast Care (Basel). 2016 Apr;11(2):133-8. doi: 10.1159/000443601. Epub 2016 Feb 8. Breast Care (Basel). 2016. PMID: 27239176 Free PMC article.
Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.
Feliu J, Artal A, González Barón M, Berrocal A, Chacón I, García de Paredes ML, Espinosa E, Ordóñez A, Zamora P, Montero JM. Feliu J, et al. Among authors: chacon i. Antimicrob Agents Chemother. 1992 Dec;36(12):2816-20. doi: 10.1128/AAC.36.12.2816. Antimicrob Agents Chemother. 1992. PMID: 1482151 Free PMC article. Clinical Trial.
Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
González-Barón M, Feliu J, Espinosa E, García-Girón C, Chacón I, Garrido P, Colmenarejo A, Ordóñez A, Zamora P. González-Barón M, et al. Among authors: chacon i. Cancer Chemother Pharmacol. 1995;36(3):255-8. doi: 10.1007/BF00685856. Cancer Chemother Pharmacol. 1995. PMID: 7781148 Clinical Trial.
[Usefulness of sialic acid as a tumor marker].
Feliú J, Daimiel E, Vicente J, Martín G, García Girón C, Chacón I, González Barón M. Feliú J, et al. Among authors: chacon i. Rev Clin Esp. 1989 May;184(8):401-3. Rev Clin Esp. 1989. PMID: 2781072 Spanish.
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A, Dueñas-García R, Jaén-Morago A, Carrasco E, Chacón I, García-Tapiador AM, Ortega-Granados AL, Martínez-Ortega E, Ribelles N, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Martínez J, Tortosa CR, Martín-Salvago MD, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Among authors: chacon i. Am J Clin Oncol. 2010 Oct;33(5):432-7. doi: 10.1097/COC.0b013e3181b4eff9. Am J Clin Oncol. 2010. PMID: 19952716 Clinical Trial.
40 results